60 Degrees Pharmaceuticals (SXTP) Operating Expenses (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Operating Expenses of $2.2 million for Q1 2026, up 3.7% year-over-year from $2.1 million in Q1 2025, and up 2.76% quarter-over-quarter from $2.1 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Operating Expenses (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Operating Expenses for 5 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 3.7% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $8.5 million (down 20.85% YoY), while the FY2025 annual figure was $8.4 million, down 16.24% from the prior year.
- Operating Expenses improved to $2.2 million in Q1 2026 per SXTP's latest filing, from $2.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $4.2 million in Q2 2024 and bottomed at $441282.0 in Q3 2022.
- Historically, Operating Expenses has averaged $1.7 million across 5 years, with a median of $1.8 million in 2023.
- Annual changes were most pronounced in 2024 — Operating Expenses jumped 533.73% — and 2025, when it slumped 55.91%.
- 60 Degrees Pharmaceuticals' Operating Expenses stood at $513022.0 in 2022, then jumped by 249.03% to $1.8 million in 2023, then gained by 23.95% to $2.2 million in 2024, then dropped by 4.79% to $2.1 million in 2025, then rose by 2.76% to $2.2 million in 2026.
- Business Quant data shows SXTP's Operating Expenses at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 541.02 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.03 Mn | 2.00 Mn | 56,798.00 | 2.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.17 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 1.86 Mn |
| Mar 31, 2025 | 2.09 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 4.22 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.79 Mn |
| Sep 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | 666,667.00 |
| Mar 31, 2023 | 899,008.00 |
| Dec 31, 2022 | 513,022.00 |
| Sep 30, 2022 | 441,282.00 |
| Jun 30, 2022 | 637,232.00 |